Compare MTRN & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRN | LNTH |
|---|---|---|
| Founded | 1931 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.5B |
| IPO Year | 2000 | 2014 |
| Metric | MTRN | LNTH |
|---|---|---|
| Price | $274.46 | $103.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $52.50 | ★ $87.00 |
| AVG Volume (30 Days) | 290.4K | ★ 875.6K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 1178.57 | N/A |
| EPS | 0.92 | ★ 1.80 |
| Revenue | N/A | ★ $343,374,000.00 |
| Revenue This Year | $15.31 | N/A |
| Revenue Next Year | $7.57 | $14.19 |
| P/E Ratio | $296.77 | ★ $57.33 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $76.09 | $47.27 |
| 52 Week High | $275.98 | $107.99 |
| Indicator | MTRN | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 80.15 | 65.25 |
| Support Level | $116.88 | $93.33 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 10.72 | 3.42 |
| MACD | 3.21 | -0.12 |
| Stochastic Oscillator | 97.57 | 68.21 |
Materion Corp offers products that include precious and non-precious specialty metals, inorganic chemicals and powders, specialty coatings, specialty engineered beryllium and copper-based alloys, beryllium composites, ceramics, and engineered clad and plated metal systems. Its segments are: Performance Materials provides beryllium and non-beryllium containing alloy systems and custom engineered parts. Electronic Materials produces chemicals, microelectronics packaging, and specialty metal products, including vapor deposition targets and preforms. Precision Optics produces thin film coatings and optical filter materials. The Other reportable segment includes unallocated corporate costs and assets. It operates in the United States, Asia, Europe, and other countries.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.